ACHV vs OWLT vs PTGX vs SNBR

For growth investors, Owlet, Inc.

(OWLT) is the stronger pick with 35. 4% revenue growth year-over-year, versus -99. 9% for Sleep Number Corporation (SNBR). Analysts rate Achieve Life Sciences, Inc. (ACHV) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protagonist Therapeutics, Inc.

(PTGX) delivered a total return of +238. 8%, compared to -97. 3% for Sleep Number Corporation (SNBR). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus ACHV's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Sleep Number Corporation's 2. 70β — meaning SNBR is approximately 976% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 70% for Achieve Life Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Owlet, Inc.

(OWLT) is pulling ahead at 35. 4% versus -99. 9% for Sleep Number Corporation (SNBR). On earnings-per-share growth, the picture is similar: Achieve Life Sciences, Inc. grew EPS -0. 8% year-over-year, compared to -541. 1% for Sleep Number Corporation. Over a 3-year CAGR, PTGX leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Achieve Life Sciences, Inc.

(ACHV) is the more profitable company, earning 0. 0% net margin versus -282. 8% for Protagonist Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACHV leads at 0. 0% versus -343. 6% for PTGX. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OWLT: 311.

5% to $20. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protagonist Therapeutics, Inc.

(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Achieve Life Sciences, Inc. (ACHV) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTGX: +744. 9%, ACHV: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACHV (Healthcare) and OWLT (Healthcare) and PTGX (Healthcare) and SNBR (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACHV is a small-cap quality compounder stock; OWLT is a mid-cap high-growth stock; PTGX is a small-cap quality compounder stock; SNBR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.